Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Drugs of Today (Barcelona, Spain : 1998)|November 6, 2013
Current treatment and future prospects for peripheral T-cell lymphomaT A Eyre, G P Collins
Bone Marrow Transplantation|September 12, 2007
Granulocyte and erythropoietic stimulating proteins after high-dose chemotherapy for myelomaT J Littlewood, G P Collins
British Journal of Haematology|November 14, 2024
Measurable residual disease-driven treatment in first-line chronic lymphocytic leukaemiaM S Davids, K H Lin, A I Mohamed, et al.
Blood Reviews|December 14, 2023
Richter's transformation: Transforming the clinical landscapeA Barrett, N Appleby, H Dreau, et al.
Clinical Medicine Insights. Blood Disorders|June 6, 2017
Toward a Biology-Driven Treatment Strategy for Peripheral T-cell LymphomaCat Hildyard, S Shiekh, Jab Browning, et al.
Journal of Internal Medicine|February 28, 2019
Impact of intended and relative dose intensity of R-CHOP in a large, consecutive cohort of elderly diffuse large B-cell lymphoma patients treated with curative intent: no difference in cumulative incidence of relapse comparing patients by ageT A Eyre, N Martinez-Calle, C Hildyard, et al.
Plos One|November 8, 2019
Correction: Long-term clinical outcomes in a cohort of patients with solitary plasmacytoma treated in the modern eraF A Sharpley, P Neffa, F Panitsas, et al.
British Journal of Cancer|October 6, 2021
Diffuse large B cell lymphoma (DLBCL) in patients older than 65 years: analysis of 3 year Real World data of practice patterns and outcomes in EnglandL Hounsome, T A Eyre, R Ireland, et al.
Bone Marrow Transplantation|June 6, 2017
High-dose chemotherapy and autologous stem cell transplantation for primary central nervous system lymphoma: a multi-centre retrospective analysis from the United KingdomS Kassam, E Chernucha, A O'Neill, et al.
European Journal of Haematology|July 13, 2004
Favourable outcome for patients with myeloid disorders treated with fludarabine-melphalan reduced-intensity conditioning and allogeneic bone marrow stem cell transplantation without the use of T-lymphocyte-depleting antibodiesR K Malladi, A J Peniket, A E Norton, et al.
Pageof 2